Session » (2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 2337

A Mediation Analysis of Tofacitinib’s Effects on SF-36: The Roles of Fatigue, Pain, Stiffness, and Mobility in Ankylosing Spondylitis

10:30AM-12:30PM: Abstract Number: 2315

Alterations in the gut microbiome in ankylosing spondylitis and their correlation with disease activity

10:30AM-12:30PM: Abstract Number: 2325

Association of Galectin-3 and Myocardial Dysfunction in Patients with Psoriatic Arthritis

10:30AM-12:30PM: Abstract Number: 2317

Cardiovascular Risk and Psoriatic Arthritis Features: Dactylitis may Predict Cardiovascular Events

10:30AM-12:30PM: Abstract Number: 2331

Coping with Rheumatic Stressors in Axial Spondyloarthritis: Association with Patient Characteristics and Disease Phenotypes and Changes Over Time

10:30AM-12:30PM: Abstract Number: 2330

Correlation of Comorbidities with Psoriatic Arthritis Duration in Elderly Veterans – A Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 2334

Development and validation analysis of a Corrected Axial Spondyloarthritis Metrology Index

10:30AM-12:30PM: Abstract Number: 2332

Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints: DAPSA44

10:30AM-12:30PM: Abstract Number: 2336

Early Axial Spondyloarthritis in Latin America: Prevalence and Regional Differences from the “ESPALDA” Multinational Registry

10:30AM-12:30PM: Abstract Number: 2324

Early Prediction of Complex Forms of Spondyloarthritis Using Artificial Intelligence: A Modeling Study Based on Routine Clinical Data

10:30AM-12:30PM: Abstract Number: 2313

From Plaque to Plaque: Bridging Oral and Systemic Inflammation in Psoriasis and PsA

10:30AM-12:30PM: Abstract Number: 2322

Gender-related Differences in Peripheral and Axial Spondyloarthritis

10:30AM-12:30PM: Abstract Number: 2326

Impact of Regular Exercise, Mobility Impairment, and Obesity on Quality of Life in Patients with Axial Spondyloarthritis: A Cross-Sectional Analysis from the Brazilian Registry of Spondyloarthritis

10:30AM-12:30PM: Abstract Number: 2329

Increased Risk of Atrial Fibrillation In Patients With Psoriasis: A Systematic Review And Meta-Analysis

10:30AM-12:30PM: Abstract Number: 2328

Increased Risk of Stroke In Patients With Psoriasis: A Systematic Review And Meta-Analysis

10:30AM-12:30PM: Abstract Number: 2309

Lifestyle behaviours and disease activity in patients with psoriatic arthritis: the Dutch south west psoriatic arthritis study

10:30AM-12:30PM: Abstract Number: 2310

Neuropeptide influence in nociception and inflammation through immune system modulation in SPA patients

10:30AM-12:30PM: Abstract Number: 2311

Obstructive Sleep Apnea Syndrome in Patients with Psoriatic Arthritis and Its Relationship with Disease Activity and Comorbidities

10:30AM-12:30PM: Abstract Number: 2307

Peripheral Manifestations In Axial And Peripheral Spondyloarthritis: A Systematic Literature Review On Their Assessment In Clinical Trials

10:30AM-12:30PM: Abstract Number: 2327

Persistent Pain in PsA: A Distinct Phenotype of Depression, Fatigue, And Catastrophizing

10:30AM-12:30PM: Abstract Number: 2308

Physical Function Mediates Most—but Not All—of the Effect of Disease Activity on Health-Related Quality of Life in Axial Spondyloarthritis: A 10-Year Longitudinal Analysis

10:30AM-12:30PM: Abstract Number: 2318

Practice Patterns and Barriers in the Referral, Management and Monitoring of Axial Spondyloarthritis: Insights from an Online Survey of Rheumatologists

10:30AM-12:30PM: Abstract Number: 2305

Predictors of Hospitalization and Emergency Department Visits Among Patients with Psoriatic Disease: Insights from the Forward Psoriasis Registry

10:30AM-12:30PM: Abstract Number: 2306

Prevalence and Clinical Significance of the Gastrointestinal Fat Halo Sign in Patients with Psoriatic Arthritis: A Cross-Sectional Study

10:30AM-12:30PM: Abstract Number: 2314

Radiographic and Ultrasonographic Assessments of Sesamoid Index in Patients with Psoriatic Arthritis

10:30AM-12:30PM: Abstract Number: 2319

Reducing selection bias while maintaining precision through an integrated analysis: 2-year longitudinal analysis of imaging outcomes in the SPondyloArthritis Caught Early cohort

10:30AM-12:30PM: Abstract Number: 2316

Sexual Dysfunction in Women with Axial Spondyloarthritis: A Meta-Analysis of FSFI Total and Domain Scores

10:30AM-12:30PM: Abstract Number: 2323

Short-term predictive factors for the development of psoriatic arthritis in patients with psoriasis: findings from a joint consultation between Rheumatology and Dermatology

10:30AM-12:30PM: Abstract Number: 2320

Sleep Disturbance in Psoriatic Arthritis: Prevalence by Minimal Disease Activity Status and Associated Clinical Factors

10:30AM-12:30PM: Abstract Number: 2312

Sociodemographic Characteristics and Healthcare Utilization in Patients with IBD-Associated Arthritis vs. IBD Alone: A Nationwide Inpatient Analysis

10:30AM-12:30PM: Abstract Number: 2335

The 14-3-3 eta AAb biomarker improves discriminative performance of CRP and HLA-B27 to differentiate people with radiographic axSpA from those with mechanical back pain.

10:30AM-12:30PM: Abstract Number: 2321

Uncovering Clinical Phenotypes of Sexual Dysfunction in Spondyloarthritis: A Multidimensional Analysis

10:30AM-12:30PM: Abstract Number: 2333

Validation of a Corrected Axial Spondyoarthritis Metrology Index in 9 Randomized Clinical Trials

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].